Company intelligence / Profile preview

GenTel BioSciences

Madison, Wisconsin, United Statesgentelbio.com ↗

Ownership: Private
Development stage: Commercial

Overview

GenTel BioSciences developed proprietary platforms and products for automated multiplex protein analysis using custom surface chemistries and software. Their technology enabled high-sensitivity detection of proteins in biomedical research, medical care, and pre-clinical drug development. The company ceased operations in March 2012 due to bankruptcy; its animal health and research tools assets were acquired by Intuitive Biosciences in May 2012.

Modalities: Protein microarrayBiologic (as platform for protein detection/analysis)
Industry: Protein Biomarker Diagnostics

Partnerships

RayBiotech (co-development of antibody arrays)Oregon Health & Science University (licensing viral antigens for simian assays)

Beyond the preview

Go deeper on GenTel BioSciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GenTel BioSciences.

Explore the full profile